STJ » Topics » Cardiac Rhythm Management (CRM)

This excerpt taken from the STJ 8-K filed Oct 21, 2009.

Cardiac Rhythm Management (CRM)

 

Total CRM sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $690 million for the third quarter of 2009, a 2 percent increase compared with the third quarter of 2008. On a currency neutral basis, total CRM sales grew 5 percent over the comparable quarter in 2008.

 

Of that total, ICD product sales were $389 million in the third quarter, a 2 percent increase compared with the third quarter of 2008. ICD revenue grew 5 percent after adjusting for the impact of foreign currency.

 

Third quarter pacemaker sales were $301 million, an increase of 1 percent from the comparable quarter of 2008. Pacemaker revenue growth was 4 percent after adjusting for the impact of foreign currency.

 





St. Jude Medical, Inc.
Global Headquarters
One St. Jude Medical Drive
St. Paul, MN 55117-9913 USA
Tel 651 756 2000
sjm.com

 

 

This excerpt taken from the STJ 8-K filed Oct 6, 2009.

Cardiac Rhythm Management (CRM)

 

Preliminary Cardiac Rhythm Management sales results, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were approximately $690 million for the third quarter of 2009, a 2 percent increase over the third quarter of 2008. On a currency neutral basis, total CRM sales grew 5 percent over the comparable period in 2008.

 

Of that total, preliminary results indicate that ICD product sales were $389 million in the third quarter, a 2 percent increase compared with the third quarter of 2008. Preliminary results indicate that ICD revenue grew 5 percent after adjusting for the impact of foreign currency.

 

Third quarter preliminary pacemaker sales results were $301 million, an increase of 1 percent from the comparable quarter of 2008. Preliminary pacemaker revenue growth was 4 percent after adjusting for the impact of foreign currency.

 

This excerpt taken from the STJ 8-K filed Jul 22, 2009.

Cardiac Rhythm Management (CRM)

 

Total CRM sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $704 million for the second quarter of 2009, a 1 percent decrease compared with the second quarter of 2008. On a currency neutral basis, total CRM sales grew 5 percent over the comparable quarter in 2008.

 

Of that total, ICD product sales were $400 million in the second quarter, a 1 percent decrease compared with the second quarter of 2008. ICD revenue grew 4 percent after adjusting for the impact of foreign currency.

 

Second quarter pacemaker sales were $304 million, a decrease of 1 percent from the comparable quarter of 2008. Pacemaker revenue growth was 6 percent after adjusting for the impact of foreign currency.

 




This excerpt taken from the STJ 8-K filed Apr 22, 2009.

Cardiac Rhythm Management (CRM)

 

Total CRM sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $676 million for the first quarter of 2009, a 7 percent increase compared with the first quarter of 2008. On a currency neutral basis, total CRM sales grew 12 percent over the comparable quarter in 2008.

 

Of that total, ICD product sales were $394 million in the first quarter, a 9 percent increase compared with the first quarter of 2008. ICD revenue grew 14 percent after adjusting for the impact of foreign currency.

 

First quarter pacemaker sales were $282 million, an increase of 4 percent from the comparable quarter of 2008. Pacemaker revenue growth was 9 percent after adjusting for the impact of foreign currency.

 

This excerpt taken from the STJ 8-K filed Jan 27, 2009.

Cardiac Rhythm Management (CRM)

 

Total Cardiac Rhythm Management sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $680 million for the fourth quarter of 2008, a 7 percent increase compared to the fourth quarter of 2007. Total CRM product sales for the full-year 2008 were $2.701 billion, representing a 14 percent increase over 2007.

 

Of that total, ICD product sales were $387 million in the fourth quarter, an 8 percent increase compared to the fourth quarter of 2007. The fourth quarter of 2007 contained a one-time revenue benefit to ICD sales due to a competitive product being off the market for a period of time. ICD product sales for the full-year 2008 were $1.534 billion, representing an 18 percent increase over 2007.

 

Fourth quarter pacemaker sales were $293 million, an increase of 5 percent from the comparable quarter of 2007. Total pacemaker sales for 2008 were $1.167 billion, up 10 percent over 2007.

 

 





St. Jude Medical, Inc.

Global Headquarters

One Lillehei Plaza

St. Paul, MN 55117-9913 USA

Tel 651 483 2000

www.sjm.com

 

This excerpt taken from the STJ 8-K filed Oct 15, 2008.

Cardiac Rhythm Management (CRM)

 

Total Cardiac Rhythm Management sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $678 million for the third quarter of 2008, a 15% increase compared to the third quarter of 2007.

 

Of that total, ICD product sales were $381 million in the third quarter, a 20% increase compared to the third quarter of 2007.

 

Third quarter pacemaker sales were $297 million, an increase of 10% from the comparable quarter of 2007.

 





St. Jude Medical, Inc.

Global Headquarters

One Lillehei Plaza

St. Paul, MN 55117-9913 USA

Tel 651 483 2000

www.sjm.com

 

 

 

This excerpt taken from the STJ 8-K filed Jul 16, 2008.

Cardiac Rhythm Management (CRM)

 

Total Cardiac Rhythm Management sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $712 million for the second quarter of 2008, a 20% increase compared to the second quarter of 2007.

 

Of that total, ICD product sales were $406 million in the second quarter, a 24% increase compared to the second quarter of 2007.

 

Second quarter pacemaker sales were $306 million, an increase of 14% from the comparable quarter of 2007.

 





St. Jude Medical, Inc.
Global Headquarters
One Lillehei Plaza
St. Paul, MN 55117-9913 USA
Tel 651 438 2000
www.sjm.com

 

This excerpt taken from the STJ 8-K filed Apr 16, 2008.

Cardiac Rhythm Management (CRM)

 

Total Cardiac Rhythm Management sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $632 million for the first quarter of 2008, a 15% increase compared to the first quarter of 2007.

 

Of that total, ICD product sales were $361 million in the first quarter, a 20% increase compared to the first quarter of 2007.




First quarter pacemaker sales were $271 million, an increase of 10% from the comparable quarter of 2007.

 

This excerpt taken from the STJ 8-K filed Jan 23, 2008.

Cardiac Rhythm Management (CRM)

 

Total Cardiac Rhythm Management sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $637 million for the fourth quarter of 2007, a 19% increase compared to the fourth quarter of 2006. Based on estimates and as previously announced, the Company believes that approximately $20 million of sales in the fourth quarter are attributable to a competitor’s recall of ICD leads and should be considered a one time event. Total CRM product sales for the full-year 2007 were $2.369 billion, representing a 15% increase over 2006.

 




Of that total, ICD product sales were $358 million in the fourth quarter, a 24% increase compared with the fourth quarter of 2006. ICD product sales for the full-year 2007 were $1.305 billion, representing a 19% increase over 2006.

 

Fourth quarter pacemaker sales were $279 million, an increase of 13% from the comparable quarter of 2006. Total pacemaker sales for 2007 were $1.064 billion, up 11% over 2006.

 

This excerpt taken from the STJ 8-K filed Oct 18, 2007.

Cardiac Rhythm Management (CRM)

 

Total Cardiac Rhythm Management sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $588 million for the third quarter of 2007, a 13% increase compared to the third quarter of 2006.

 

Of that total, ICD product sales were $318 million in the third quarter, a 17% increase compared to the third quarter of 2006.

 

Third quarter pacemaker sales were $270 million, an increase of 9% from the comparable quarter of 2006.





This excerpt taken from the STJ 8-K filed Jul 18, 2007.

Cardiac Rhythm Management (CRM)

 

Total Cardiac Rhythm Management sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $595 million for the second quarter of 2007, a 15% increase compared to the second quarter of 2006.

 

Of that total, ICD product sales were $327 million in the second quarter, an 18% increase compared to the second quarter of 2006.

 

Second quarter pacemaker sales were $268 million, an increase of 11% from the comparable quarter of 2006.

 




This excerpt taken from the STJ 8-K filed Apr 19, 2007.

Cardiac Rhythm Management (CRM)

 

Total Cardiac Rhythm Management sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $549 million for the first quarter of 2007, a 14% increase compared to the first quarter of 2006.

 

Of that total, ICD product sales were $302 million in the first quarter, a 15% increase over the comparable quarter of 2006.

 

First quarter pacemaker sales were $247 million, an increase of 12% from the comparable quarter of 2006.




 

This excerpt taken from the STJ 8-K filed Jan 25, 2007.

Cardiac Rhythm Management (CRM)

Total CRM sales were $535 million for the fourth quarter of 2006, a 4% increase compared to the fourth quarter of 2005. Total CRM product sales for the full-year 2006 were $2.056 billion, representing a 7% increase over 2005. In 2006, St. Jude Medical gained the No. 2 market share position in the CRM category of products, which includes implantable cardioverter defibrillator (ICD) and pacemaker products.

 

Fourth quarter ICD product sales were $289 million, a 3% increase over the comparable quarter of 2005. ICD product sales for the full-year 2006 were $1.1 billion, representing a 9% increase over 2005.

 

Fourth quarter pacemaker sales were $246 million, an increase of 6% from the comparable quarter of 2005. Total pacemaker sales for 2006 were $956 million, up 4% over 2005.

 

"Cardiac Rhythm Management (CRM)" elsewhere:

Boston Scientific (BSX)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki